Company Market Research Report: Syngene International Limited

Company Overview

Name, Mission, and Vision

Name: Syngene International Limited

Mission: To contribute to the evolution of scientific research using skills, technology, and experience to find solutions to the world’s most complex challenges.

Vision: To be a world-class partner delivering innovative scientific solutions.

Founding Details

Founding Year: 1993

Founder: No information available

Key People

Jonathan Hunt: Managing Director and Chief Executive Officer

Andrew Webster: Chief Human Resources Officer

Alok Mehrotra: Chief Quality Officer

Kenneth Barr: Senior Vice President – Discovery Services

Alex Del Priore: Senior Vice President - Manufacturing

Sibaji Biswas: Executive Director and Chief Financial Officer

Caroline Hempstead: Head of Customer Centricity and Special Projects

Pramuch Goel: Head of Corporate Affairs

Headquarters

Location: Bangalore, India

Number of Employees

Employees: 5656 scientists

Revenue

Total Income for FY24: INR 35,792 million

Known For

Syngene is known for being a contract research, development, and manufacturing organization (CRDMO) providing integrated scientific services from early discovery to commercial supply.

Products and Services

Product Offerings

Syngene offers a wide range of services and products across different business areas:

1. Discovery Services

Description: Services span from early-stage research to drug candidate delivery for further development. Service areas include Chemistry, Biology, Safety Assessment & Toxicology, and Computational & Data Sciences for small molecules, and recombinant DNA engineering, cell line development, hybridoma technology, next-generation sequencing, and protein sciences for biologics.

Features:

Extensive early-stage research capabilities

Integrated informatics and advanced informatics capabilities

GLP packages and specialty studies

2. Development Services

Description: Full-scale services for small molecules and biologics covering preclinical development, API and drug product development, and clinical development.

Features:

Drug development services from lead generation to clinical supplies

Formulation services and analytical development

Clinical trials and regulatory support

3. Manufacturing Services

Description: Manufacturing capabilities for small molecules and biologics with GMP compliance.

Features:

End-to-end manufacturing solutions including HPAPI and novel intermediates

Broad range of reactors and diverse chemistries handling

Biologics facilities catering to multi-product production campaigns with single-use technology platforms

4. Dedicated Centers

Description: Offering dedicated multi-disciplinary scientific teams to support specific client needs.

Features:

Dedicated R&D centers for customized partnerships

Specialization in various therapeutic areas and flexible business models

Recent Developments

Recent Achievements

1. Awards and Recognition

Asia Pacific Biologics CMO Excellence Awards 2024: Adjudged Best Biologics CMO in South Asia by IMAPAC.

EcoVadis Sustainability Rating 2024: Silver rating in the EcoVadis sustainability index, ranking among the top 15% of companies assessed worldwide.

CDMO Leadership Awards 2024: Winner under Reliability and Compatibility categories for exceeding customer expectations.

2. Sustainability Initiatives

Science-Based Targets Commitment: Syngene's GHG emissions reduction targets are validated, aiming to reduce absolute Scope 1 and 2 GHG emissions by 54.6% by FY2033.

3. Contracts and Partnerships

New Partnership with Zoetis: Signed a 10-year agreement for commercial manufacturing of Librela® (a monoclonal antibody for osteoarthritis in dogs).

New Products and Features

1. New Facility Launch

Biologics Manufacturing Facility: Operational for US and European customers starting mid-year 2024.

2. Service Enhancements

Launch of Enhanced Protein Production Platform: Aimed at rapid and enhanced protein production to meet market demands.

3. Expansion Milestones

Expansion of Discovery Chemistry Facility in Hyderabad: Adding 52,000 sq. ft. state-of-the-art R&D center focused on discovery chemistry services.

Upcoming Events

NLS Days 2024: 17th to 19th September, Sweden

Protein Degradation & Targeting Undruggables Congress Europe: 19th to 20th September

BioProcess International Boston: 23rd to 26th September, Boston

BioFoward: 24th September, London

Contract Pharma: 2024 Contracting & Outsourcing Conference: 26th & 27th September, New Brunswick

Discovery on Target 2024: 30th September to 3rd October

Conclusion

Syngene International Limited positions itself as a leading innovation-led CRDMO with a robust portfolio of services across drug discovery, development, and manufacturing. With a sharp focus on sustainability and integrated solutions, Syngene continues to expand its footprint globally backed by strategic partnerships and strong corporate governance.